Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (Q37718225)

22 August 2017

0 references

1 reference

title

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (English)

1 reference

22 August 2017

0 references

0 references

1 reference

Astrid Wiens

1

1 reference

22 August 2017

Rafael Venson

2

1 reference

22 August 2017

Cassyano J Correr

3

1 reference

22 August 2017

Michel Fleith Otuki

4

1 reference

22 August 2017

Roberto Pontarolo

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

30

1 reference

22 August 2017

4

1 reference

22 August 2017

339-353

1 reference

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

22 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.4.339

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.4.339

1 reference

22 August 2017

1 reference